These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 29789969)
1. Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Li D; McCall LM; Hahn OM; Hudis CA; Cohen HJ; Muss HB; Jatoi A; Lafky JM; Ballman KV; Winer EP; Tripathy D; Schneider B; Barry W; Dickler MN; Hurria A Breast Cancer Res Treat; 2018 Sep; 171(2):325-334. PubMed ID: 29789969 [TBL] [Abstract][Full Text] [Related]
2. TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. Vaklavas C; Roberts BS; Varley KE; Lin NU; Liu MC; Rugo HS; Puhalla S; Nanda R; Storniolo AM; Carey LA; Saleh MN; Li Y; Delossantos JF; Grizzle WE; LoBuglio AF; Myers RM; Forero-Torres A; Breast Cancer Res; 2020 Feb; 22(1):22. PubMed ID: 32070401 [TBL] [Abstract][Full Text] [Related]
3. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037 [TBL] [Abstract][Full Text] [Related]
4. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. Martín M; Loibl S; Hyslop T; De la Haba-Rodríguez J; Aktas B; Cirrincione CT; Mehta K; Barry WT; Morales S; Carey LA; Garcia-Saenz JA; Partridge A; Martinez-Jañez N; Hahn O; Winer E; Guerrero-Zotano A; Hudis C; Casas M; Rodriguez-Martin C; Furlanetto J; Carrasco E; Dickler MN; ; ; Eur J Cancer; 2019 Aug; 117():91-98. PubMed ID: 31276981 [TBL] [Abstract][Full Text] [Related]
5. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). Dickler MN; Barry WT; Cirrincione CT; Ellis MJ; Moynahan ME; Innocenti F; Hurria A; Rugo HS; Lake DE; Hahn O; Schneider BP; Tripathy D; Carey LA; Winer EP; Hudis CA J Clin Oncol; 2016 Aug; 34(22):2602-9. PubMed ID: 27138575 [TBL] [Abstract][Full Text] [Related]
6. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658 [TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2. Verma S; O'Shaughnessy J; Burris HA; Campone M; Alba E; Chandiwana D; Dalal AA; Sutradhar S; Monaco M; Janni W Breast Cancer Res Treat; 2018 Aug; 170(3):535-545. PubMed ID: 29654415 [TBL] [Abstract][Full Text] [Related]
8. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F; Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983 [TBL] [Abstract][Full Text] [Related]
9. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. O'Shaughnessy J; Petrakova K; Sonke GS; Conte P; Arteaga CL; Cameron DA; Hart LL; Villanueva C; Jakobsen E; Beck JT; Lindquist D; Souami F; Mondal S; Germa C; Hortobagyi GN Breast Cancer Res Treat; 2018 Feb; 168(1):127-134. PubMed ID: 29164421 [TBL] [Abstract][Full Text] [Related]
10. A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). Mayer IA; Prat A; Egle D; Blau S; Fidalgo JAP; Gnant M; Fasching PA; Colleoni M; Wolff AC; Winer EP; Singer CF; Hurvitz S; Estévez LG; van Dam PA; Kümmel S; Mundhenke C; Holmes F; Babbar N; Charbonnier L; Diaz-Padilla I; Vogl FD; Sellami D; Arteaga CL Clin Cancer Res; 2019 May; 25(10):2975-2987. PubMed ID: 30723140 [TBL] [Abstract][Full Text] [Related]
11. Everolimus Plus Letrozole for Treatment of Patients With HR Safra T; Kaufman B; Kadouri L; Efrat Ben-Baruch N; Ryvo L; Nisenbaum B; Evron E; Yerushalmi R Clin Breast Cancer; 2018 Apr; 18(2):e197-e203. PubMed ID: 29097108 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Finn RS; Crown JP; Ettl J; Schmidt M; Bondarenko IM; Lang I; Pinter T; Boer K; Patel R; Randolph S; Kim ST; Huang X; Schnell P; Nadanaciva S; Bartlett CH; Slamon DJ Breast Cancer Res; 2016 Jun; 18(1):67. PubMed ID: 27349747 [TBL] [Abstract][Full Text] [Related]
13. First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial. Janni W; Alba E; Bachelot T; Diab S; Gil-Gil M; Beck TJ; Ryvo L; Lopez R; Tsai M; Esteva FJ; Auñón PZ; Kral Z; Ward P; Richards P; Pluard TJ; Sutradhar S; Miller M; Campone M Breast Cancer Res Treat; 2018 Jun; 169(3):469-479. PubMed ID: 29404806 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E Lancet Oncol; 2019 Sep; 20(9):1226-1238. PubMed ID: 31402321 [TBL] [Abstract][Full Text] [Related]
15. Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. Ballhausen A; Wheler JJ; Karp DD; Piha-Paul SA; Fu S; Pant S; Tsimberidou AM; Hong DS; Subbiah V; Holley VR; Huang HJ; Brewster AM; Koenig KB; Ibrahim NK; Meric-Bernstam F; Janku F Clin Cancer Res; 2021 Mar; 27(5):1247-1255. PubMed ID: 33115815 [TBL] [Abstract][Full Text] [Related]
16. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Blackwell KL; André F; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Petrakova K; Hart LL; Villanueva C; Chan A; Jakobsen E; Nusch A; Burdaeva O; Grischke EM; Alba E; Wist E; Marschner N; Favret AM; Yardley D; Bachelot T; Tseng LM; Blau S; Xuan F; Souami F; Miller M; Germa C; Hirawat S; O'Shaughnessy J N Engl J Med; 2016 Nov; 375(18):1738-1748. PubMed ID: 27717303 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. Ruhstaller T; Giobbie-Hurder A; Colleoni M; Jensen MB; Ejlertsen B; de Azambuja E; Neven P; Láng I; Jakobsen EH; Gladieff L; Bonnefoi H; Harvey VJ; Spazzapan S; Tondini C; Del Mastro L; Veyret C; Simoncini E; Gianni L; Rochlitz C; Kralidis E; Zaman K; Jassem J; Piccart-Gebhart M; Di Leo A; Gelber RD; Coates AS; Goldhirsch A; Thürlimann B; Regan MM; J Clin Oncol; 2019 Jan; 37(2):105-114. PubMed ID: 30475668 [TBL] [Abstract][Full Text] [Related]
18. Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab. Magbanua MJM; Savenkov O; Asmus EJ; Ballman KV; Scott JH; Park JW; Dickler M; Partridge A; Carey LA; Winer EP; Rugo HS Clin Cancer Res; 2020 Sep; 26(18):4911-4920. PubMed ID: 32586939 [TBL] [Abstract][Full Text] [Related]
19. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Sonke GS; Hart LL; Campone M; Erdkamp F; Janni W; Verma S; Villanueva C; Jakobsen E; Alba E; Wist E; Favret AM; Bachelot T; Hegg R; Wheatley-Price P; Souami F; Sutradhar S; Miller M; Germa C; Burris HA Breast Cancer Res Treat; 2018 Feb; 167(3):659-669. PubMed ID: 29058175 [TBL] [Abstract][Full Text] [Related]
20. Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR Brufsky A; Mitra D; Davis KL; Nagar SP; McRoy L; Cotter MJ; Stearns V Clin Breast Cancer; 2019 Oct; 19(5):317-325.e4. PubMed ID: 31104984 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]